pdufa.bio

Linerixibat

Page updated ·next FDA decision on the calendar ·Data as of Nov 12, 2026 2:24 AM ET

The FDA approved Linerixibat on Mar 19, 2026. 1 FDA decision on record below. Every date links its source.

GSK catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Mar 19, 2026 ✓ ApprovedGSK

Questions

When is Linerixibat's next FDA decision or readout?

No upcoming catalyst is on our calendar for Linerixibat; 1 FDA decision is on record below.

What happened at Linerixibat's most recent FDA decision?

On Mar 19, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has Linerixibat been approved by the FDA?

Yes. The FDA approved an application for Linerixibat on Mar 19, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.